Celcuity, based in Minneapolis, employs 55 staff and went public on September 20, 2017. Its lead candidate, gedatolisib, targets specific cancer pathways and is in trials for advanced breast and prostate cancer.
Celcuity (CELC) reported a negative EPS surprise in its most recent quarterly earnings. For the most recent quarter, Celcuity's actual EPS was -$0.70, missing the estimate of -$0.67 per share, resulting in a -5.12% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
